查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088505

抗病毒療法市場：按藥物類別、給藥途徑、病毒類型、治療方法和最終用戶分類 - 全球市場預測（2026-2032 年）

Antiviral Therapeutics Market by Drug Class, Route Of Administration, Virus Type, Route of Administration, Treatment Type, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗病毒療法市場將成長至 1,570.2 億美元，複合年成長率為 8.57%。

主要市場統計數據
基準年（2025 年） 882.9億美元
預計年份（2026年） 950.6億美元
預測年份（2032年） 1570.2億美元
複合年成長率（） 8.57%

抗病毒療法仍是全球感染疾病防治的關鍵支柱，涵蓋愛滋病毒、B型肝炎、C型肝炎、流感、皰疹病毒、SARS-CoV-2 以及新出現的病毒威脅。抗病毒療法市場由臨床驗證的藥物類別組成，例如核苷類和核苷酸類似物、蛋白酶抑製劑、聚合酵素抑製劑、整合酶抑製劑和病毒進入抑製劑，以及聯合治療。

全球衛生組織報告的疾病負擔，包括愛滋病毒、病毒性肝炎、季節性流感以及世界衛生組織認可的流行性呼吸道病毒等持續存在的挑戰，進一步推動了這一需求。隨著診斷、監測和快速治療途徑的改進，抗病毒藥物的重要性日益凸顯，它們不僅是急性期治療的干預手段，也是增強抗疫能力、維持醫院容量、制定合理使用抗菌藥物策略以及在人群層面控制疾病的長期工具。

抗病毒藥物領域的根本性變革

抗病毒治療領域正從被動治療模式轉向更快速、更有針對性且更擴充性的治療。丙型肝炎直接抗病毒藥物已證實，短期根治性治療在臨床上是可行的。同時，近期愛滋病治療也證實了持續聯合治療、藥物依從性創新、抗藥性監測以及基於指南的慢性病管理等方面的價值。

人工智慧對抗病毒藥物創新所產生的累積影響

人工智慧（AI）正在對抗病毒藥物發現、開發和生命週期管理的各個階段產生累積影響。 AI驅動的蛋白質建模、虛擬篩檢、分子設計和預測毒理學正在幫助研究人員更有效率地確定目標和化合物的優先級，尤其是在病毒突變率和抗藥性途徑需要快速迭代的情況下。

全球抗病毒藥物需求的區域分析。

亞太地區憑藉其龐大的患者群體、不斷擴大的醫療服務覆蓋範圍以及印度和中國強大的生產能力，在抗病毒療法市場中扮演著核心角色。日本、韓國和澳洲也憑藉其先進的研究、監測系統和成熟的管理體制做出貢獻。北美地區則持續保持商業化和創新的領先地位，這得益於公共生物醫學研究、完善的監管流程、臨床試驗基礎設施以及應對疫情的專款。

影響抗病毒治療市場的策略：重點團體分析

隨著東南亞地區感染疾病監測系統、學名藥取得途徑以及區域間衛生合作的不斷完善，東協市場的重要性日益凸顯。這一趨勢在呼吸道病毒、肝炎、愛滋病和登革熱等疾病的防治準備方面尤其明顯。海灣合作理事會（GCC）正透過投資醫療基礎設施、集中採購、引入數位醫療以及製定國家衛生安全戰略，積極推進抗病毒藥物的防控準備工作。同時，歐盟也正在透過聯合採購、監管協調、突發公共衛生事件緊急準備以及跨境監測等舉措，加強其協調應對能力。

抗病毒藥物市場擴張的主要國際趨勢

美國在抗病毒藥物研發經費、生物技術創新、法規核准、臨床試驗和市場推廣方面處於主導地位，而加拿大則優先考慮循證報銷、公共衛生應急準備和公平獲取。墨西哥和巴西是重要的市場准入管道，公共採購、當地流行病學狀況、生產政策和價格可負擔性都會影響抗病毒藥物的引進。在歐洲，英國、德國、法國、義大利和西班牙擁有先進的醫療保健體系，並具備完善的監管、報銷機制和臨床研究能力，而俄羅斯則優先考慮國內生產，並始終將感染疾病防治作為戰略重點。

為抗病毒藥物行業的領導者提供的實用建議

產業領導者應優先考慮建立多元化的抗病毒藥物組合，以應對慢性病毒性疾病和急性、高感染疾病。投資應集中於具有口服製劑、長效給藥頻譜、聯合治療、抗藥性意識開發以及可靠的臨床、生產和監管途徑的廣譜候選藥物。

分析方法和證據框架

本報告採用系統性的二手資料研究途徑編製而成，資料來源包括經檢驗的公共衛生、監管、臨床和產業資訊來源。證據來源包括全球衛生組織的最新動態、法規核准和指南、臨床試驗註冊資訊、同儕審查文獻、治療指南、公共採購資訊以及經認可的監測數據。

結論：抗病毒療法的策略性展望

抗病毒療法正進入一個更具策略性的階段，其特點是人們對更精準的藥物設計、更快的疫情應對、更強力的監測和更廣泛的應用前景充滿期待。愛滋病、肝炎、流感和皰疹病毒等成熟的治療領域將繼續滿足持續的臨床需求，而新冠肺炎疫情則永久性地提升了可擴展的門診抗病毒療法和應對疫情準備的重要性。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：人工智慧（AI）的累積影響（2026 年）

第7章：抗病毒治療藥物市場：依藥物類別分類

  • 聚合酵素抑制劑
  • 蛋白酶抑制劑
  • 整合酶抑制劑
  • 融合抑制劑

第8章：抗病毒治療藥物市場：依給藥途徑分類

  • 吸入
  • 注射
  • 口服
  • 外用

第9章：抗病毒療法市場：依病毒類型分類

  • HIV
  • 肝炎病毒
  • 流感
  • 皰疹病毒
  • 呼吸道病毒

第10章：抗病毒治療藥物市場：依給藥途徑分類

  • 口服
  • 靜脈
  • 外用
  • 鼻內

第11章 抗病毒治療市場：依治療方法分類

  • 根治性治療
  • 維持治療
  • 預防性治療

第12章：抗病毒治療市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 居家醫療
  • 公共衛生計劃

第13章：抗病毒治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：抗病毒治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 抗病毒治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）

第17章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Alkem Laboratories Limited
  • AstraZeneca PLC
  • Atea Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Cocrystal Pharma, Inc.
  • Daiichi Sankyo Company, Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Syngene International Limited
  • Takeda Pharmaceutical Company Limited
  • Themis Medicare Ltd.
  • Venatorx Pharmaceuticals, Inc.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-037F3DB2591D

The Antiviral Therapeutics Market is projected to grow by USD 157.02 billion at a CAGR of 8.57% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 88.29 billion
Estimated Year [2026] USD 95.06 billion
Forecast Year [2032] USD 157.02 billion
CAGR (%) 8.57%

Antiviral therapeutics remain a critical pillar of global infectious disease management, spanning HIV, hepatitis B, hepatitis C, influenza, herpesviruses, SARS-CoV-2, and emerging viral threats. The antiviral therapeutics landscape is shaped by clinically validated drug classes such as nucleoside and nucleotide analogs, protease inhibitors, polymerase inhibitors, integrase inhibitors, entry inhibitors, and combination regimens that reduce viral replication, limit disease progression, and support public health preparedness.

Demand is reinforced by verified disease burden reported by global health agencies, including WHO-recognized ongoing challenges in HIV, viral hepatitis, seasonal influenza, and epidemic-prone respiratory viruses. As diagnostics, surveillance, and rapid treatment pathways improve, antiviral drugs are increasingly positioned not only as acute-care interventions but also as long-term tools for outbreak resilience, hospital capacity protection, antimicrobial stewardship-adjacent strategies, and population-level disease control.

Transformative Shifts in the Antiviral Therapeutics Landscape

The antiviral therapeutics landscape is moving from reactive treatment models toward faster, more targeted, and more scalable care. Direct-acting antivirals for hepatitis C demonstrated that short-course curative therapy is clinically viable, while modern HIV therapy confirmed the value of durable combination regimens, adherence innovation, resistance monitoring, and guideline-driven chronic disease management.

COVID-19 accelerated structural change by normalizing emergency authorizations, adaptive clinical trial designs, test-to-treat models, and government-supported procurement. Industry competition is now focused on oral antivirals, long-acting formulations, pan-viral mechanisms, improved safety profiles, resistance barriers, and medicines that can be deployed rapidly across outpatient settings before disease progression increases hospitalization risk.

Cumulative Impact of Artificial Intelligence on Antiviral Innovation

Artificial intelligence is becoming a cumulative force across antiviral drug discovery, development, and lifecycle management. AI-enabled protein modeling, virtual screening, molecular design, and predictive toxicology help researchers prioritize targets and compounds more efficiently, especially when viral mutation rates and resistance pathways require rapid iteration.

Beyond discovery, AI supports clinical trial site selection, patient stratification, pharmacovigilance signal detection, real-world evidence generation, and supply-demand planning. Its value is strongest when paired with validated laboratory assays, human clinical expertise, transparent governance, and regulatory-grade data quality, ensuring that speed does not compromise safety, efficacy, reproducibility, or patient trust.

Key Regional Insights Across Global Antiviral Demand

Asia-Pacific is central to antiviral therapeutics because of high patient volumes, expanding healthcare access, and strong manufacturing capacity across India and China, with Japan, South Korea, and Australia contributing advanced research, surveillance systems, and regulatory maturity. North America remains a leading commercialization and innovation hub, supported by public biomedical research, established regulatory pathways, clinical trial infrastructure, and pandemic preparedness funding.

Europe benefits from coordinated regulatory review, strong public health systems, vaccination and surveillance networks, and established clinical research capacity, while Latin America, led by Brazil and Mexico, is focused on broader access, public procurement, infectious disease monitoring, and affordability. The Middle East, particularly Gulf economies, is investing in health security, specialty care, and centralized procurement, whereas Africa represents a high-need region where HIV, hepatitis, respiratory outbreaks, and emerging infection control depend on affordability, donor-supported programs, diagnostics, local capacity building, and resilient supply chains.

Key Group Insights Shaping Antiviral Therapeutics Strategy

ASEAN markets are gaining relevance as infectious disease surveillance, generic medicine access, and regional health cooperation improve across Southeast Asia, particularly for respiratory viruses, hepatitis, HIV, and dengue-related preparedness. The GCC is advancing antiviral readiness through healthcare infrastructure investment, centralized procurement, digital health adoption, and national health security strategies, while the European Union is strengthening coordinated response capabilities through joint procurement, regulatory alignment, health emergency preparedness, and cross-border surveillance initiatives.

BRICS countries are influential because they combine large patient populations, active clinical research, and major pharmaceutical manufacturing bases, particularly in China, India, and Brazil, with strategic focus on access, self-reliance, and domestic innovation. The G7 continues to shape global antiviral priorities through research funding, regulatory science, pandemic preparedness commitments, and support for global health programs, while NATO members increasingly view antiviral stockpiles, biosecurity, medical logistics, and continuity of care as components of health resilience and national security.

Key Country Insights for Antiviral Therapeutics Expansion

The United States leads in antiviral research funding, biotechnology innovation, regulatory approvals, clinical trial activity, and commercial uptake, while Canada emphasizes evidence-based reimbursement, public health preparedness, and equitable access. Mexico and Brazil are important access markets where public procurement, local epidemiology, manufacturing policy, and affordability shape antiviral adoption. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced healthcare systems with strong regulatory, reimbursement, and clinical research capabilities, while Russia maintains domestic production priorities and strategic interest in infectious disease control.

China and India are essential to global antiviral supply, with China expanding novel drug development, clinical research capacity, and domestic regulatory modernization, while India serves as a major producer of generics and active pharmaceutical ingredients supporting global access. Japan prioritizes high-quality clinical evidence, antiviral preparedness, and care for an aging population; Australia supports advanced surveillance and regional health security across the Indo-Pacific; and South Korea combines biotechnology growth, manufacturing capability, rapid diagnostics, and digital health infrastructure to support antiviral innovation.

Actionable Recommendations for Antiviral Industry Leaders

Industry leaders should prioritize diversified antiviral portfolios that address both chronic viral diseases and acute outbreak-prone infections. Investment should focus on oral agents, long-acting delivery systems, combination therapy, resistance-informed development, and broad-spectrum candidates with credible clinical, manufacturing, and regulatory pathways.

Executives should also strengthen diagnostic partnerships, test-to-treat distribution, AI governance, pharmacovigilance, and manufacturing redundancy. Competitive advantage will increasingly depend on the ability to balance premium innovation with equitable access, align with public health agencies, support evidence-based reimbursement, and build supply chains resilient enough to support both routine care and emergency demand surges.

Research Methodology and Evidence Framework

This executive summary is developed through a structured secondary research approach using verified public health, regulatory, clinical, and industry sources. Evidence inputs include global health agency updates, regulatory authority approvals and guidance, clinical trial registries, peer-reviewed literature, treatment guidelines, public procurement information, and recognized surveillance data.

Insights are triangulated across disease burden, therapeutic standards, pipeline trends, geographic access factors, procurement behavior, manufacturing capacity, and policy developments. The methodology prioritizes data-backed interpretation, avoids unsupported market claims, and frames strategic conclusions around observable therapeutic, regulatory, clinical, and public health evidence.

Conclusion: Strategic Outlook for Antiviral Therapeutics

Antiviral therapeutics are entering a more strategic phase defined by precision drug design, faster outbreak response, stronger surveillance, and broader access expectations. Established therapy areas such as HIV, hepatitis, influenza, and herpesviruses continue to support sustained clinical need, while COVID-19 has permanently elevated the importance of scalable outpatient antivirals and pandemic preparedness.

Future leadership will depend on scientific differentiation, AI-enabled development, resistance management, regional access planning, and reliable manufacturing. Organizations that integrate clinical innovation with public health alignment, regulatory discipline, and equitable access will be best positioned to support long-term value in antiviral drugs and global infectious disease control.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antiviral Therapeutics Market, by Drug Class

  • 7.1. Polymerase Inhibitors
  • 7.2. Protease Inhibitors
  • 7.3. Integrase Inhibitors
  • 7.4. Fusion Inhibitors

8. Antiviral Therapeutics Market, by Route Of Administration

  • 8.1. Inhalation
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Topical

9. Antiviral Therapeutics Market, by Virus Type

  • 9.1. HIV
  • 9.2. Hepatitis Viruses
  • 9.3. Influenza
  • 9.4. Herpes Viruses
  • 9.5. Respiratory Viruses

10. Antiviral Therapeutics Market, by Route of Administration

  • 10.1. Oral
  • 10.2. Intravenous
  • 10.3. Topical
  • 10.4. Nasal

11. Antiviral Therapeutics Market, by Treatment Type

  • 11.1. Curative Therapies
  • 11.2. Maintenance Therapies
  • 11.3. Prophylactic Therapies

12. Antiviral Therapeutics Market, by End-User

  • 12.1. Hospitals
  • 12.2. Specialty Clinics
  • 12.3. Homecare Settings
  • 12.4. Public Health Programs

13. Antiviral Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Antiviral Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiviral Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. AbbVie Inc.
  • 17.3. Alkem Laboratories Limited
  • 17.4. AstraZeneca PLC
  • 17.5. Atea Pharmaceuticals, Inc.
  • 17.6. Aurobindo Pharma Limited
  • 17.7. Bristol-Myers Squibb Company
  • 17.8. Cipla Ltd.
  • 17.9. Cocrystal Pharma, Inc.
  • 17.10. Daiichi Sankyo Company, Ltd.
  • 17.11. Dr. Reddy's Laboratories Ltd.
  • 17.12. Eli Lilly and Company
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. Gilead Sciences, Inc.
  • 17.15. GlaxoSmithKline plc
  • 17.16. Hetero Labs Limited
  • 17.17. Johnson & Johnson Services Inc.
  • 17.18. Merck & Co., Inc.
  • 17.19. Novartis AG
  • 17.20. Pfizer Inc.
  • 17.21. Sanofi S.A.
  • 17.22. Sun Pharmaceutical Industries Limited
  • 17.23. Syngene International Limited
  • 17.24. Takeda Pharmaceutical Company Limited
  • 17.25. Themis Medicare Ltd.
  • 17.26. Venatorx Pharmaceuticals, Inc.
  • 17.27. Viatris Inc.
  • 17.28. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTEGRASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTEGRASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTEGRASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FUSION INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FUSION INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FUSION INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HIV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEPATITIS VIRUSES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEPATITIS VIRUSES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEPATITIS VIRUSES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HERPES VIRUSES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HERPES VIRUSES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HERPES VIRUSES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RESPIRATORY VIRUSES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RESPIRATORY VIRUSES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESPIRATORY VIRUSES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CURATIVE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CURATIVE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CURATIVE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MAINTENANCE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MAINTENANCE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MAINTENANCE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROPHYLACTIC THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROPHYLACTIC THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROPHYLACTIC THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PUBLIC HEALTH PROGRAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PUBLIC HEALTH PROGRAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PUBLIC HEALTH PROGRAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 181. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 202. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 209. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 211. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 216. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 223. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 230. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 244. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 251. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 258. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 260. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 265. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 267. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)